Intraoperative radiation therapy

Intraoperative Radiation Therapy Market - Growth, Trends & Forecast 2020 - ResearchAndMarkets.com

Retrieved on: 
Friday, July 31, 2020
Professional services, Consulting, Medicine, Health, Intraoperative radiation therapy, Intraoperative electron radiation therapy, Radiation therapy, Therapy, Surgery, Targeted intra-operative radiotherapy, Electron therapy

The "Intraoperative Radiation Therapy Market - Growth, Trends, and Forecast (2020 - 2025)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Intraoperative Radiation Therapy Market - Growth, Trends, and Forecast (2020 - 2025)" report has been added to ResearchAndMarkets.com's offering.
  • Intraoperative radiation therapy (IORT) is an intensive radiation treatment that's administered during surgery.
  • Electron Intraoperative radiation therapy or Intraoperative electron radiation therapy (IOERT) is the application of electron radiation directly to the residual tumor or tumor bed during cancer surgery.
  • Hence, as high demand is met by the presence of global players in the region, the market is further expected to increase.

iCAD Hosts Virtual Roundtable Event on Breast Cancer Surgery and Targeted Radiation During COVID-19

Retrieved on: 
Monday, June 1, 2020
Medicine, RTT, Health, Clinical medicine, Breast surgery, Intraoperative radiation therapy, Radiation therapy, Breast cancer, Cancer, Targeted intra-operative radiotherapy, Intraoperative electron radiation therapy

(NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced it will host a free virtual roundtable event for clinicians, titled The Impact of COVID-19 on Breast Cancer Surgery and Targeted Radiation Therapy, on June 4, 2020 at 7 pm ET/4 pm PT.

Key Points: 
  • (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced it will host a free virtual roundtable event for clinicians, titled The Impact of COVID-19 on Breast Cancer Surgery and Targeted Radiation Therapy, on June 4, 2020 at 7 pm ET/4 pm PT.
  • Xoft breast IORT is a single-fraction therapy option that allows select early-stage breast cancer patients to replace weeks of daily radiation with one treatment, delivered at the time of surgery.
  • A number of breast cancer patients at our facility have had their treatment delayed due to the COVID-19 pandemic.
  • This virtual roundtable event is a part of larger series of webinars hosted by iCAD in recent weeks, featuring leading experts in breast cancer detection and treatment.

iCAD Presents Positive New Clinical Data for Xoft Brain IORT at American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program

Retrieved on: 
Wednesday, May 13, 2020
Medicine, Radiation therapy, Cancer, Clinical medicine, Intraoperative radiation therapy, Glioblastoma, Brachytherapy, American Society of Clinical Oncology, Blastoma, Intraoperative electron radiation therapy, Targeted intra-operative radiotherapy

(NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced positive new clinical data supporting the Xoft Axxent Electronic Brachytherapy (eBx) System for the treatment of glioblastoma multiforme (GBM) will be presented at the American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program, which will take place May 29-31, 2020.

Key Points: 
  • (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced positive new clinical data supporting the Xoft Axxent Electronic Brachytherapy (eBx) System for the treatment of glioblastoma multiforme (GBM) will be presented at the American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program, which will take place May 29-31, 2020.
  • As of December 2019, 8 patients from the IORT group were still alive, whereas none of the patients in the EBRT group survived.
  • Researchers concluded that IORT of recurrent GBM is feasible and provides encouraging local progression-free and overall survival, with a manageable toxicity profile.
  • After researching this modality for nearly four years, we are greatly encouraged by these clinical results and the benefits this treatment offers to patients.

First Brain Tumor Treated with Xoft IORT in the United States

Retrieved on: 
Tuesday, February 11, 2020
Medicine, Health, Clinical medicine, Medical physics, Cancer treatments, Intraoperative radiation therapy, Radiation therapy, Adjuvant therapy, Brachytherapy, Therapy, Brain tumor, Intraoperative electron radiation therapy

(NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the first metastatic brain tumor was treated in the U.S. with intraoperative radiation therapy (IORT) using the Xoft Axxent Electronic Brachytherapy (eBx) System.

Key Points: 
  • (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the first metastatic brain tumor was treated in the U.S. with intraoperative radiation therapy (IORT) using the Xoft Axxent Electronic Brachytherapy (eBx) System.
  • The IORT group (A) was treated with a single fraction of radiation immediately following surgical resection, without chemotherapy or temozolomide following surgery.
  • The comparison group (B) was treated with routine postoperative adjuvant chemotherapy +/- concomitant or sequential EBRT.
  • As of September 2019, nine patients were still alive from group A, whereas none of the patients in group B survived.

iCAD Showcases Technology for Cancer “Discovery to Recovery” including ProFound AI Platform and Xoft System at Arab Health 2020 in Dubai

Retrieved on: 
Monday, January 27, 2020
Breast imaging, Medicine, Clinical medicine, Radiation therapy, Tomosynthesis, X-ray computed tomography, Cancer, Intraoperative radiation therapy, DBT, ICAD, Mammography, Breast cancer

Arab Health is the largest gathering of healthcare companies, technologies, products and services in the Middle East and North African (MENA) region.

Key Points: 
  • Arab Health is the largest gathering of healthcare companies, technologies, products and services in the Middle East and North African (MENA) region.
  • iCADs Breast Health Solutions suite includes ProFound AI for Digital Breast Tomosynthesis (DBT), as well as software solutions for 2D mammography and breast density.
  • Additionally, the Company offers world-class treatment planning programs, developed for both the Xoft controller and general IORT with the Xoft System.
  • Accessed via https://www.icadmed.com/assets/dmm253-reader-studies-results-rev-a.pdf
    Headquartered in Nashua, NH, iCAD is a global medical technology leader providing innovative cancer detection and therapy solutions.

IntraOp and Alliant Dermatology bring electron beam therapy to skin cancer patients in Florida

Retrieved on: 
Thursday, January 9, 2020
Radiation therapy, Medical physics, Physics, Physical sciences, Electron therapy, Condensed matter physics, Intraoperative radiation therapy, Electron, Dermatology

SUNNYVALE, Calif., Jan. 9, 2020 /PRNewswire/ -- IntraOp Medical Corporation announced today that Alliant Dermatology in The Villages, Florida has commenced treating skin cancer patients with its latest technologya Mobetron electron beam linear accelerator optimized to treat skin lesions.

Key Points: 
  • SUNNYVALE, Calif., Jan. 9, 2020 /PRNewswire/ -- IntraOp Medical Corporation announced today that Alliant Dermatology in The Villages, Florida has commenced treating skin cancer patients with its latest technologya Mobetron electron beam linear accelerator optimized to treat skin lesions.
  • IntraOp, the leading innovator in compact electron therapy devices, announced plans in early 2019 to bring hospital grade electron therapy to dermatology clinics.
  • To bring Superficial Electron Therapy to their patients, Alliant Dermatology partnered with Oncology Physicians of Florida for prescribing and managing treatments.
  • "We are delighted to be partnering with Alliant Dermatology as we bring the benefits of electron beam therapy to skin cancer patients."

CivaDerm™ - CivaTech Oncology’s New Skin Cancer Therapy Product Receives FDA Clearance

Retrieved on: 
Monday, September 30, 2019
Biotechnology, Surgery, Oncology, FDA, Health, Medical devices, Medicine, Radiation therapy, Health, Medical physics, Clinical medicine, Brachytherapy, Therapy, Skin cancer, Management of prostate cancer, Intraoperative radiation therapy

CivaTech Oncologys new device, CivaDerm has received FDA clearance.

Key Points: 
  • CivaTech Oncologys new device, CivaDerm has received FDA clearance.
  • CivaDerm is a temporary radiation therapy product designed for intraoperative or surface radiation to treat skin cancer and other lesions.
  • The product can be applied like a bandage to provide a low dose rate (LDR) brachytherapy treatment option for skin cancer patients.
  • Radiation therapy for common skin cancers is already a popular treatment option, with excellent cosmetic outcomes and treatment success rates.

University Hospital Salzburg Selects IntraOp® Mobetron®

Retrieved on: 
Tuesday, September 17, 2019
Health, Medicine, Medical physics, Intraoperative radiation therapy, Radiation therapy, Paracelsus Medical University, Electron therapy, Therapy, Paracelsus, Jonas Salk, Intraoperative electron radiation therapy, Targeted intra-operative radiotherapy

SUNNYVALE, Calif., September 17, 2019 /PRNewswire-PRWeb/ --IntraOp Medical Corporation announced today that University Hospital Salzburg (SALK) Austria has purchased the IntraOp's third generation Mobetron and advanced treatment planning software, to pursue implementing Image Guided Electron Therapy (IGET) for intraoperative radiation therapy (IORT) clinically.

Key Points: 
  • SUNNYVALE, Calif., September 17, 2019 /PRNewswire-PRWeb/ --IntraOp Medical Corporation announced today that University Hospital Salzburg (SALK) Austria has purchased the IntraOp's third generation Mobetron and advanced treatment planning software, to pursue implementing Image Guided Electron Therapy (IGET) for intraoperative radiation therapy (IORT) clinically.
  • The Paracelsus Medical University Hospital Salzburg has been a pioneering thought leader in IORT for more than 20 years.
  • "We are delighted to be partnering with Professor Sedlmayer and the team at University Hospital Salzburg and providing the most advanced IORT technology available today," said Derek T. DeScioli, Chief Executive Officer of IntraOp Medical Corporation.
  • IntraOp will be providing to University Hospital Salzburg its third generation Mobetron technology including automatic soft docking, Prelude IORT Management system and Radiance 3D treatment planning as well high density radiotranslucent applicators compatible with Image Guided Electron Therapy.

iCAD Exhibiting New Updates and Enhanced Xoft Platform at ASTRO Including Single-Fraction IORT Solution for the Treatment of Early-Stage Breast Cancer

Retrieved on: 
Monday, September 16, 2019
Radiation therapy, RTT, Medicine, Intraoperative radiation therapy, Health, Medical specialties, Breast cancer, Cancer, Targeted intra-operative radiotherapy, Intraoperative electron radiation therapy

As cancer treatment becomes increasingly targeted and value-based, iCADs Xoft System continues to be an established trailblazer in this revolutionary trend towards more personalized cancer treatment.

Key Points: 
  • As cancer treatment becomes increasingly targeted and value-based, iCADs Xoft System continues to be an established trailblazer in this revolutionary trend towards more personalized cancer treatment.
  • Leading experts will be available in the Xoft booth throughout ASTRO and SROA to discuss their clinical experience using the technology across various cancer types.
  • As a single-fraction treatment therapy for early-stage breast cancer, Xoft IORT is a viable and verified treatment option that appears well-aligned with the core elements of the proposed model.
  • At ASTRO, findings from a Vanderbilt University School of Medicine study supporting Xoft IORT for early-stage breast cancer will be presented on Sunday, September 15 at 1:15 pm CT in the Breast Cancer Track.

Global $68 Million Intraoperative Radiation Therapy Markets, 2024 by Method, Products & Services, Application

Retrieved on: 
Thursday, September 12, 2019
Health sciences, Health, Radiation therapy, Articles, Medical physics, Radioactivity, Radiobiology, Therapy, Intraoperative radiation therapy

The global intraoperative radiation therapy market is projected to reach USD 68 million by 2024 from USD 48 million in 2019, at a CAGR of 7.0%.

Key Points: 
  • The global intraoperative radiation therapy market is projected to reach USD 68 million by 2024 from USD 48 million in 2019, at a CAGR of 7.0%.
  • This report studies the intraoperative radiation therapy market based on method, products & services, application, and region.
  • The growing incidence of cancer, supportive government initiatives, and the implementation of intraoperative radiation therapy market training programs & conferences/symposiums are the major factors propelling the demand for intraoperative radiation therapy market products in Europe.
  • Furthermore, several key market players are focusing on enhancing their intraoperative radiation therapy market products to improve the quality of patient care across Europe.